Albert Nikolai, Melau Marianne, Jensen Heidi, Emborg Charlotte, Jepsen Jens Richardt Mollegaard, Fagerlund Birgitte, Gluud Christian, Mors Ole, Hjorthøj Carsten, Nordentoft Merete
Copenhagen University Hospital, Mental Health Centre Copenhagen, Research Unit, Hellerup, Denmark
Copenhagen University Hospital, Mental Health Centre Copenhagen, Research Unit, Hellerup, Denmark.
BMJ. 2017 Jan 12;356:i6681. doi: 10.1136/bmj.i6681.
To compare the effects of five years of specialised early intervention (SEI) treatment for first episode schizophrenia spectrum disorder with the standard two years of SEI plus three years of treatment as usual.
Randomised, superiority, parallel group trial with blinded outcome assessment. Randomisation was centralised and computerised with concealed randomisation sequence carried out at an external site.
Participants were recruited from six OPUS teams in Denmark between 2009 and 2012. OPUS teams provide SEI treatment to all patients diagnosed with a schizophrenia spectrum disorder in Denmark.
400 participants (51% women) with a mean age of 25.6 (standard deviation 4.3) were randomised to five years of SEI (experimental intervention; n=197) or to two years of SEI plus three years of treatment as usual (control; n=203).
OPUS treatment consists of three core elements-modified assertive community treatment, family involvement, and social skill training-with a patient-case manager ratio of no more than 12:1. For participants randomised to five years of OPUS treatment, the treatment was largely unchanged. Participants randomised to the control group were mostly referred to community health centres after two years of SEI treatment.
Follow-up assessments were conducted five years after start of OPUS treatment. Primary outcome was negative symptoms measured on the scale for assessment of negative symptoms (avolition-apathy, anhedonia, alogia, and affective blunting). Secondary outcomes were remission of both negative and psychotic symptoms, psychotic symptoms, suicidal ideation, substance abuse, compliance with medical treatment, adherence with treatment, client satisfaction, days in hospital care, and labour market affiliation.
Levels of negative symptoms did not differ between the intervention group and control group (1.72 v 1.81 points; estimated mean difference -0.10 (95% confidence interval -0.33 to 0.13), P=0.39). Participants receiving five years of OPUS treatment were more likely to remain in contact with specialised mental health services (90.4% v 55.6%, P<0.001), had higher client satisfaction (estimated mean difference 2.57 points (95% confidence interval 1.36 to 3.79), P<0.001), and had a stronger working alliance (estimated mean difference 5.56 points (95% confidence interval 2.30 to 8.82), P=0.001) than the control group.
This trial tests SEI treatment for up to five years for patients with first episode schizophrenia spectrum disorder; previous trials have found treatment effects for programmes lasting from one to three years. The prolonged SEI treatment had few effects, which could be due to the high level of treatment provided to control participants and the late start of specialised treatment.Trial registration Clinicaltrial.gov NCT00914238.
比较针对首发精神分裂症谱系障碍进行五年的专科早期干预(SEI)治疗与标准的两年SEI加三年常规治疗的效果。
随机、优效性、平行组试验,采用盲法结局评估。随机化在外部站点进行集中式计算机化操作,并采用隐藏随机序列。
2009年至2012年期间,从丹麦的六个OPUS团队招募参与者。OPUS团队为丹麦所有被诊断为精神分裂症谱系障碍的患者提供SEI治疗。
400名参与者(51%为女性),平均年龄25.6岁(标准差4.3),被随机分为接受五年SEI治疗(实验性干预;n = 197)或两年SEI加三年常规治疗(对照组;n = 203)。
OPUS治疗包括三个核心要素——改良的积极社区治疗、家庭参与和社交技能训练,患者与个案管理员的比例不超过12:1。对于随机接受五年OPUS治疗的参与者,治疗基本保持不变。随机分配到对照组的参与者在接受两年SEI治疗后大多被转介至社区健康中心。
在OPUS治疗开始五年后进行随访评估。主要结局是使用阴性症状评估量表(意志缺乏-淡漠、快感缺失、言语贫乏和情感迟钝)测量的阴性症状。次要结局包括阴性和精神病性症状的缓解、精神病性症状、自杀观念、药物滥用、遵医嘱治疗、坚持治疗、患者满意度、住院天数以及劳动力市场参与情况。
干预组和对照组的阴性症状水平无差异(1.72对1.81分;估计平均差异-0.10(95%置信区间-0.33至0.13),P = 0.39)。接受五年OPUS治疗的参与者更有可能继续接受专科心理健康服务(90.4%对55.6%,P < 0.001),患者满意度更高(估计平均差异2.57分(95%置信区间1.36至3.79),P < 0.001),且工作联盟更强(估计平均差异5.56分(95%置信区间2.30至8.82),P = 0.001)。
本试验对首发精神分裂症谱系障碍患者进行长达五年的SEI治疗进行了测试;之前的试验发现持续一至三年的治疗方案具有治疗效果。延长的SEI治疗效果甚微,这可能是由于为对照组参与者提供的治疗水平较高以及专科治疗开始较晚。试验注册Clinicaltrial.gov NCT00914238。